Tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growthfactor-binding protein 7 (IGFBP7) have gained recognition as clinical biomarkers of AKI, collectively known as NephrocheckTM commercially (79). The gene discussed is TIMP2; the disease is acute kidney injury.